670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC)

Ravdin, Peter M.; Erban, John K.; Overmoyer, Beth; Budd, G. Thomas; Hutchins, Laura; Ee, Lower; Laufman, Leslie Rodgers; Sundaram, Suchitra; Urba, W J; Olsen, Steven R.; Meyers, Marlene; Jones, Steven W.

doi:10.1016/s1359-6349(03)90701-4

Cited by 31 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[12][13][14] Indeed, up to 50% of cancer patients are resistant or become PAPer tyPe rePOrt resistant to PTX during drug administration. [15][16][17] Therefore, it is compelling to overcome taxane resistance or to find alternative therapeutic strategies that would kill tumor cells more efficiently than taxanes. Over the past decades great translational effort has been directed toward the development of drugs that target the mitotic spindle assembly or function (such as Eg5, Aurora, Plk1, or cyclin-dependent kinases).…”

Section: Introductionmentioning

confidence: 99%

Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy

et al. 2013

View full text Add to dashboard Cite

Microtubule-poisoning drugs, such as Paclitaxel (or taxol, PtX), are powerful and commonly used anti-neoplastic agents for the treatment of several malignancies. PtX triggers cell death, mainly through a mitotic arrest following the activation of the spindle assembly checkpoint (SAC). Cells treated with PtX slowly slip from this mitotic block and die by mitotic catastrophe. However, cancer cells can acquire or are intrinsically resistant to this drug, posing one of the main obstacles for PtX clinical effectiveness. In order to override PtX resistance and increase its efficacy, we investigated both the enhancement of mitotic slippage and the block of mitotic exit.to test these opposing strategies, we used physiological hyperthermia (Ht) to force exit from PtX-induced mitotic block and the anaphase-promoting complex/cyclosome (APC/C) inhibitor, protAMe, to block mitotic exit. We observed that application of Ht on PtX-treated cells forced mitotic slippage, as shown by the rapid decline of cyclin B levels and by microscopy analysis. Similarly, Ht induced mitotic exit in cells blocked in mitosis by other antimitotic drugs, such as Nocodazole and the Aurora A inhibitor MLN8054, indicating a common effect of Ht on mitotic cells. On the other hand, protAMe prevented mitotic exit of PtX and MLN8054 arrested cells, prolonged mitosis, and induced apoptosis. In addition, we showed that protAMe prevented Ht-mediated mitotic exit, indicating that stress-induced APC/C activation is necessary for Ht-induced mitotic slippage.Finally, Ht significantly increased PtX cytotoxicity, regardless of cancer cells' sensitivity to PtX, and this activity was superior to the combination of PtX with pro-tAMe. Our data suggested that forced mitotic exit of cells arrested in mitosis by anti-mitotic drugs, such as PtX, can be a more successful anticancer strategy than blocking mitotic exit by inactivation of the APC/C.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Docetaxel is highly active when given as a short, intermittent infusion. The theoretical evidence supporting docetaxel has been borne out by the results of the randomized trial previously discussed (Table 2) [12]. The results of the ECOG 1199 trial, a randomized trial comparing AC followed by paclitaxel with AC followed by docetaxel in the adjuvant setting, are eagerly awaited.…”

Section: Which Is the Preferred Taxane?mentioning

confidence: 99%

“…A degree of support for this hypothesis was recently provided by the results of the first direct randomized comparison between paclitaxel and docetaxel. In that study, reported by Ravdin and colleagues [12], docetaxel, 100 mg/m 2 , was compared with paclitaxel, 175 mg/m 2 , given every 3 weeks in a group of 449 women with advanced breast cancer and prior anthracycline treatment. While the difference in overall response rate (ORR) did not reach statistical significance, the time to progression (TTP) and OS time were significantly superior for docetaxel ( Table 2).…”

Section: Anthracycline Pretreated Patientsmentioning

confidence: 99%

Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

2004

View full text Add to dashboard Cite

In the 10 years since their initial licensing in Europe, the taxanes, paclitaxel and docetaxel, have emerged as fundamental drugs in the treatment of breast cancer. Clinically meaningful benefits were first shown in the metastatic setting, and large-scale exploration of their roles in the adjuvant therapy of early-stage disease is ongoing. Benefits have been seen in the neoadjuvant setting as well, mainly with docetaxel. This paper reviews the current roles of the taxanes in the treatment of metastatic and early-stage breast cancer. Also addressed are outstanding issues involving optimal dosing and sequencing, as well as a discussion of the relative merits of each agent in this setting. Clinicians should choose a taxane-based regimen for their patients with breast cancer based on consideration of the pharmacokinetics, clinical activity, and dosing schedule that best meets the patients' needs. At the current time, the pharmacokinetic profile, consistent positive clinical results, and convenience of an intermittent, short-infusion schedule have made docetaxel the preferred taxane for many clinicians treating patients with breast cancer. The Oncologist 2004;9(suppl 2): [24][25][26][27][28][29][30][31][32] The Oncologist 2004;9(suppl 2):24-32 www.TheOncologist.com Correspondence: John Crown, M.D., Medical Oncology Research Unit, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Telephone: 353-1-2094839; Fax: 353-1-2837719; e-mail: john.crown@icorg.ie Received March 11, 2004; accepted for publication March 22, 2004 accepted for publication March 22, . ©1083-7159/2004 INTRODUCTIONThe taxanes have emerged as critically important drugs in the treatment of patients with breast cancer. The relatively accelerated clinical development of these agents can be attributed to the rapid collection of an unprecedented amount of data from numerous large, high-quality prospective random assignment trials, trials that involved literally tens of thousands of patients.

show abstract

“…The inference from these data is that docetaxel may be superior to paclitaxel in MBC. Indeed, a trial directly comparing the two confirmed superior TTP and overall survival favouring docetaxel, but with a higher incidence of myelosuppression (41).…”

Section: Chemotherapy For Metastatic Breast Cancer (Mbc)mentioning

confidence: 99%

Chemotherapy for breast cancer (Review)

Hassan¹

2010

Oncol Rep

150

View full text Add to dashboard Cite

Abstract. The use of cytotoxic chemotherapy in both advanced and early stage breast cancer has made significant progress in the last 10 years with several landmark studies identifying clear survival benefits for newer therapies. In spite of these developments the optimal approach for any specific patient can not be determined from a literature review or decision-making algorithm alone. Treatment choices are predominantly based on practice determined by individual or collective experience and the historical development of treatment within a locality. The improvement in the understanding of the molecular biological basis of breast cancer provides possible targets for novel therapies. Personalised therapies for breast cancer based on the molecular characteristics of the tumour could improve the risk:benefit ratio of current therapies. Increased improvements in the use of a panel of biomarkers will thus not only move us towards tailored therapies but will also spare a group of patients that do not benefit from adjuvant chemotherapy. At the same time a better understanding of tumour biology will also streamline the development of new regimens for those who are unlikely to benefit from existing drugs. This review will focus on the evidence for the use of chemotherapy and highlight advances in chemotherapy treatments with the addition of new and novel drugs marching into our clinics as standard treatments based on evidence from clinical trials and from a better understanding of tumour biology that has transformed the outlook in breast cancer in both the adjuvant and metastatic setting.

show abstract

670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC)

Cited by 31 publications

References 0 publications

Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy

Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy

Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

Chemotherapy for breast cancer (Review)

Contact Info

Product

Resources

About